Article preview from Start-Up - June 2008
Mpathy Medical Devices is focused on one of the hottest medtech markets--women's health. The company's physiologically compatible and ultra-lightweight Smartmesh technology targets the female anatomy to treat urinary stress incontinence and pelvic organ prolapse. Although Smartmesh is based on the same polypropylene material that has been used as mesh by other companies for many years for hernia repair and pelvic floor reconstruction, Mpathy Medical has innovated certain characteristics that encourage new tissue growth. Find out more.
Continue reading "Mpathy Medical Devices Ltd." »
Article preview from IN VIVO - June 2008
Bioabsorbable stents arouse great enthusiasm among both interventionalists and industry executives, because they have one major advantage over current stents, both bare metal and drug-eluting: they obviate the need for a permanent implant when only a temporary scaffolding effect is needed. Many stent companies are hedging their bets, working on stents that incorporate both drug elution and bioabsorbability--but not Paris-based Arterial Remodeling Technologies, which is arguing that natural healing, not drug therapy, is the best approach to therapeutically active stents.
Continue reading "ART: Bucking the Trend in Bioabsorbable Stents " »
From the May 28, 2007, issue of "The Gray Sheet"
OrbusNeich hopes to lead a new wave of stent technology with its Genous Bio-engineered R-Stent, which the firm says is safer than existing drug-eluting stents because it has a natural antibody coating instead of a drug-eluting polymer.
David Camp, OrbusNeich's VP-strategic marketing and business development, spoke to "The Gray Sheet" about the device's potential May 23 from Barcelona, host of the EuroPCR conference May 22-25.
Genous was CE marked in August 2005 and is being evaluated in a number of studies in Europe. The Hong Kong firm met with FDA in March to discuss a pivotal trial to support U.S. approval of the device.
Continue reading "OrbusNeich Says "Bio-Engineered" Stent May Be Solution To Thrombosis Risk" »
From the March 26, 2007, issue of "The Gray Sheet"
Edwards Lifesciences will soon begin a 600-patient U.S. pivotal clinical trial for its Sapien transcatheter aortic replacement heart valve at Columbia University Medical Center and the Cleveland Clinic, the company says.
Announced March 20, FDA clearance allows the company to enroll the first 40 patients at up to eight centers in the PARTNER trial (Placement of AoRTic traNscathetER valves). Edwards plans to expand the trial to 15 additional sites, pending FDA clearance.
Continue reading "Edwards Set To Launch "Two-Trials-In-One" For Sapien Percutaneous Valve" »